US4096256AExpiredUtility
7-Acyl-3-(ureidoalkyl substituted tetrazolylthiomethyl) cephalosporins, antibacterial compositions containing them, and methods of treating bacterial infections using them
Est. expiryDec 9, 1995(expired)· nominal 20-yr term from priority
Inventors:David A. Berges
C07D 257/04A61P 31/04
51
PatentIndex Score
1
Cited by
5
References
11
Claims
Abstract
The compounds of this invention are cephalosporins having various acyl substituents at the 7-position and an ureidoalkyl substituted tetrazolylthiomethyl group at the 3-position of the cephem nucleus and intermediates for the preparation thereof. The 7-acylated compounds have antibacterial activity.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A compound of the formula: ##STR8## in which: R 1 is an acyl group of the formula: ##STR9## where: Z is methyl, trifluoromethyl, trifluoroethyl, pyridyl or cyanomethyl; m is zero to two; and n is two to five, or a non-toxic pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 in which n is two.
3. A compound according to claim 1 in which Z is trifluoromethyl or cyanomethyl.
4. A compound according to claim 3, said compound being 7-cyanomethylthioacetamido-3-[1-(2-ureidoethyl)tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid.
5. A compound according to claim 3, said compound being 7-trifluoromethylthioacetamido-3-[1-(2-ureidoethyl)tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid.
6. An antibacterial pharmaceutical composition comprising a compound as claimed in claim 1 and a pharmaceutically acceptable carrier therefor.
7. An antibacterial pharmaceutical composition comprising a compound as claimed in claim 4 and a pharmaceutically acceptable carrier therefor.
8. A method of treating bacterial infections comprising administering internally by injection to an infected or susceptible warm-blooded animal an antibacterially effective but nontoxic dose of a compound as claimed in claim 1.
9. An antibacterial pharmaceutical composition comprising a compound as claimed in claim 5 and a pharmaceutically acceptable carrier therefor.
10. A method as claimed in claim 8, in which the compound is 7-cyanomethylthioacetamido-3-[1-(2-ureidoethyl)-tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid.
11. A method as claimed in claim 8, in which the compound is 7-trifluoromethylthioacetamido-3-[1-(2-ureidoethyl)tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid.Join the waitlist — get patent alerts
Track US4096256A — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.